Dr. Longo is Chairman of the Board and founder of PharmatrophiX. Dr.
Longo received his MD in 1981 and PhD in Neurosciences in 1983 from UC San Diego. He completed his neurology training in the Department of Neurology at UC San Francisco where he was then recruited as an assistant professor and promoted to professor and vice chair. From 2001 to 2005 he was chair of the Department of Neurology at the University of North Carolina-Chapel Hill and since 2006 has served as chair of the Department of Neurology and Neurological Sciences at Stanford. With support from the Alzheimer's Association, Alzheimer's Drug Discovery Foundation, the NIH and generous gifts, he and his team, along with co-inventor Dr. Stephen Massa MD, PhD at UCSF & the SFVAMC, pioneered the development of small molecules targeting neurotrophin receptors for the treatment of Alzheimer's disease, traumatic brain injury and other disorders. In 2005, while at UNC, he founded PharmatrophiX. Dr. Longo serves in many advisory capacities including NIH study sections, editorial boards, foundations, grant review boards and therapy evaluations.
Frank M. Longo, M.D., Ph.D.
Anne Longo has been CEO of PharmatrophiX since 2010 and also serves
part-time as the Senior Director of Development for Neurology &
Neurological Sciences at Stanford University. Following her graduation from Stanford University, she led programs at the NIH and at the Alliance for Aging Research in Washington DC. Ms. Longo also served in business
development at Age Wave and at Charles Schwab in San Francisco. As CEO of PharmatrophiX, Ms. Longo develops and executes funding models,
oversees finances working with the CFO, manages commercial projects and supervises contract research organization (CRO) projects. She has worked in medical development since March 2002 where she served as the Director of Development for the Department of Neurology at the University of North Carolina-Chapel Hill and then worked as the Director of Development at Stanford University for Women's Cancer and the Neurosciences beginning in May 2006. In her twelve years of medical development, Ms. Longo has raised over $60M in new gifts including nine endowed medical school professorships.
PharmatrophiX engages teams of advisors consisting of senior industry and academic experts in all
stages of drug development and in global strategies and approaches in Alzheimer's and
other neurological diseases.
The Alzheimer's Drug Discovery Foundation (ADDF) has
been a source of several peer-reviewed grants supporting PTX technology and its
peer-reviewed Biotechnology Program maintains scientific oversight and an equity
position in PTX.
The Alzheimer Association Part-the-Cloud Program has provided peer-reviewed funding in support of the successful completion of the PTX LM11A-31 phase 1 trial.
John Autrey has been the CFO of PharmatophiX since 2008 providing accounting services, financial reporting and cash forecasting to the management team and investors. Mr. Autrey works with PharmatrophiX’s CEO on tax, insurance, banking, legal and other administrative issues. Mr. Autrey, based in Research Triangle Park, is a co-founder of Rankin McKenzie LLC, one of North Carolina’s largest and most trusted financial management firms. He has extensive experience in assisting early stage companies and also serves as the CFO for a start-up CRO. He recently was the CFO for two medical device companies--TEM Systems, Inc. and Oncoscope Inc. A North Carolina native, Mr. Autrey earned his Bachelor’s degree from the University North Carolina – Chapel Hill and a Master’s in Business Administration from Wake Forest University.